Diurnal motor variations to repeated doses of levodopa in Parkinson's disease

被引:57
作者
Bonuccelli, U
Del Dotto, P
Lucetti, C
Petrozzi, L
Bernardini, S
Gambaccini, G
Rossi, G
Piccini, P
机构
[1] Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy
[2] Natl Res Council, Inst Clin Physiol, Unit Epidemiol & Biostat, Pisa, Italy
[3] Hammersmith Hosp, MRC, London, England
关键词
Parkinson's disease; levodopa; tolerance;
D O I
10.1097/00002826-200001000-00006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Patients with Parkinson's disease (PD) in long-term levodopa therapy often complain of worsening of motor symptoms in the afternoon and evening. The pathophysiology of this phenomenon is not known. We evaluated the motor response to repeated doses of levodopa during a 12-hour period in 52 parkinsonian patients (19 de novo, 20 stable, and 13 wearing-off). On the day of the study, all patients received standard doses of levodopa/carbidopa at 8:00 a.m., 12:00 noon, and 4:00 p.m. Motor measurements such as lapping test, walking time, and tremor score, and blood samples for levodopa and 3-O-methyldopa (30MD) plasma analysis, were performed hourly. Mean motor scores and pharmacokinetic data, evaluated for a period of 3 hours after each levodopa dose, were compared. In de novo patients, we did not observe diurnal changes in motor score, whereas a progressive daytime worsening was visible in stable and wearing-off patients. No significant difference in levodopa pharmacokinetics after each levodopa dose was observed within each patient group, whereas 30MD plasma levels significantly increased with repeated levodopa administrations. However, no significant correlation between motor scores and 30MD plasma levels was observed, suggesting that the diminishing motor response to afternoon and evening doses of levodopa in patients in long-term levodopa therapy does nor relate to the pharmacokinetics of the drug. It is possible that this phenomenon may be an expression of the occurrence of tolerance to repeated doses of levodopa.
引用
收藏
页码:28 / 33
页数:6
相关论文
共 26 条
[1]   FLUCTUATING PARKINSONS-DISEASE - TREATMENT WITH THE LONG-ACTING DOPAMINE AGONIST CABERGOLINE [J].
AHLSKOG, JE ;
MUENTER, MD ;
MARAGANORE, DM ;
MATSUMOTO, JY ;
LIEBERMAN, A ;
WRIGHT, KF ;
WHEELER, K .
ARCHIVES OF NEUROLOGY, 1994, 51 (12) :1236-1241
[2]   A COMBINED LEVODOPA TEST AS A USEFUL METHOD FOR EVALUATING THE EFFICACY OF DOPAMINE AGONISTS - APPLICATION TO PERGOLIDE AND BROMOCRIPTINE [J].
BONNET, AM ;
SERRE, I ;
MARCONI, R ;
AGID, Y ;
DUBOIS, B .
MOVEMENT DISORDERS, 1995, 10 (05) :668-671
[3]   SUSTAINED ENTERAL ADMINISTRATION OF LEVODOPA INCREASES AND INTERRUPTED INFUSION DECREASES LEVODOPA DOSE REQUIREMENTS [J].
CEDARBAUM, JM ;
SILVESTRI, M ;
KUTT, H .
NEUROLOGY, 1990, 40 (06) :995-997
[4]   ACUTE EFFECTS OF PULSATILE LEVODOPA ADMINISTRATION ON CENTRAL DOPAMINE PHARMACODYNAMICS [J].
DAVIS, TL ;
BRUGHITTA, G ;
BARONTI, F ;
MOURADIAN, MM .
NEUROLOGY, 1991, 41 (05) :630-633
[5]   Gastric emptying in Parkinson's disease: Patients with and without response fluctuations [J].
Djaldetti, R ;
Baron, J ;
Ziv, I ;
Melamed, E .
NEUROLOGY, 1996, 46 (04) :1051-1054
[6]   LEVODOPA PHARMACOKINETIC MECHANISMS AND MOTOR FLUCTUATIONS IN PARKINSONS-DISEASE [J].
FABBRINI, G ;
JUNCOS, J ;
MOURADIAN, MM ;
SERRATI, C ;
CHASE, TN .
ANNALS OF NEUROLOGY, 1987, 21 (04) :370-376
[7]  
Fahn S., 1989, DRUGS TREATMENT PARK, P385, DOI [10.1007/978-3-642-73899-9_14, DOI 10.1007/978-3-642-73899-9_14]
[8]   DIURNAL DIFFERENCES IN RESPONSE TO ORAL LEVODOPA [J].
FRANKEL, JP ;
PIRTOSEK, Z ;
KEMPSTER, PA ;
BOVINGDON, M ;
WEBSTER, R ;
LEES, AJ ;
STERN, GM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (11) :948-950
[9]   PERIPHERAL PHARMACOKINETICS OF LEVODOPA IN UNTREATED, STABLE, AND FLUCTUATING PARKINSONIAN-PATIENTS [J].
GANCHER, ST ;
NUTT, JG ;
WOODWARD, WR .
NEUROLOGY, 1987, 37 (06) :940-944
[10]   TIME COURSE OF TOLERANCE TO APOMORPHINE IN PARKINSONISM [J].
GANCHER, ST ;
NUTT, JG ;
WOODWARD, WR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (05) :504-510